Islam Saqib 4

What Happened
Islam Saqib, a director of ARS Pharmaceuticals, was granted a derivative award of 30,000 shares on June 24, 2026. The reported acquisition price is $0.00 (derivative award), and the grant will vest in full on the earlier of June 24, 2027 or the date of the issuer's 2027 annual meeting of stockholders.

Key Details

• Transaction date: 2026-06-24; filing date (Form 4): 2026-06-26 (timely filed).
• Type: Award/Grant (derivative); amount: 30,000 shares; reported acquisition price: $0.00.
• Vesting: Full vesting on earlier of June 24, 2027 or the Issuer’s 2027 annual meeting (footnote F1).
• Shares owned after transaction: not specified in this filing.
• No sale or exercise occurred — this is a compensation grant, not a market purchase or sale.

Context
This is a compensation-related derivative grant (likely stock options or RSUs) that vests over time; it does not represent an immediate purchase or sale of stock. Such awards are common for directors and reflect compensation rather than a direct signal to buy or sell shares.